SORBILINE

Dosage

Children: Refer to specific drug information for detailed dosage recommendations.

Adults: Refer to specific drug information for detailed dosage recommendations.

Mechanism of action

The mechanism of action varies depending on the specific drug that 'contains' certain active ingredients. Each compound will have its own unique pharmacological pathway and target within the body, which can include receptor modulation, enzyme inhibition, or other biochemical interactions.

Pharmacodynamics

Pharmacodynamics will depend on the active ingredients in the formulation. It generally encompasses the biochemical and physiological effects of the drug and its mechanisms of action, including the relationship between drug concentration and effect.

Pharmacokinetics

Pharmacokinetics involves the absorption, distribution, metabolism, and excretion of the specific active ingredients within the formulation. This can vary significantly based on the drug's chemical properties, route of administration, and individual patient factors.

Pregnancy

Consult with a healthcare provider before use, as safety during pregnancy has not been established.

Breast-feeding

Consult with a healthcare provider before use, as it is not known if this drug is excreted in human milk.

Storage

Store in a cool, dry place away from direct sunlight. Keep out of reach of children.

Dosage

Children: Refer to specific formulation guidelines as excipients are not dosed individually.

Adults: Refer to specific formulation guidelines as excipients are not dosed individually.

Mechanism of action

Excipients do not have a pharmacological mechanism of action in the way active drugs do; instead, they facilitate the delivery and absorption of the active pharmaceutical ingredients (APIs) in the body, improving the overall pharmacokinetics and bioavailability of the medication.

Pharmacodynamics

As excipients are inactive, they do not have pharmacodynamic properties. However, the choice of excipient can influence the release profile of the active ingredient, alter the drug's stability, and affect the solubility and bioavailability of the drug, which are critical for ensuring that the intended therapeutic effects are achieved.

Pharmacokinetics

Excipients generally do not undergo pharmacokinetic processes like absorption, distribution, metabolism, and excretion as active drugs do. They are usually considered inert, but their physical and chemical properties can influence the pharmacokinetics of the active ingredients they accompany. For example, some excipients may enhance the solubility of the active ingredient, facilitating better absorption in the gastrointestinal tract.

Pregnancy

Safety during pregnancy has not been established for all excipients. Some may pose risks while others are generally considered safe. Consultation with healthcare professionals is advised.

Breast-feeding

The safety of excipients during breastfeeding varies depending on the specific excipient. It is essential to consult healthcare professionals.

Storage

Excipients should be stored according to the specific requirements of the formulation they are a part of. Generally, they should be kept in a cool, dry place away from light.

Indications

• Constipation
• Diagnostic aid in colonoscopy preparation
• Management of hyperosmolality in various conditions

Dosage

Children: For children, the dosage should be determined based on age and condition, and it is advised to refer to the BNF for Children for specific dosing guidelines.

Adults: The typical dose for adults is 30 to 150 mL of sorbitol solution (70%) taken orally, as needed, usually before bedtime.

Mechanism of action

Sorbitol exerts its laxative effect by drawing water into the large intestine, thereby stimulating bowel movements. It acts as a hygroscopic agent, pulling water from tissues into the feces, which reflexively stimulates evacuation. In metabolic pathways, sorbitol is produced from glucose via aldose reductase and is converted to fructose by sorbitol dehydrogenase, with implications in diabetic complications such as retinopathy.

Pharmacodynamics

Sorbitol's laxative effect results from its osmotic properties, which increase the water content of the stool and soften it, facilitating easier passage. Additionally, sorbitol can induce apoptosis in certain cancer cell lines, indicating potential therapeutic implications beyond its laxative use. The modulation of intracellular signaling pathways through the regulation of proteins such as Bax and Bcl-2 suggests a complex role in cellular health and disease.

Pharmacokinetics

Sorbitol is poorly absorbed in the gastrointestinal tract, which contributes to its efficacy as a laxative. It is metabolized in the liver, primarily through the polyol pathway. The absorption and distribution of sorbitol are affected by its osmotic properties, leading to increased intestinal water retention. Its elimination is primarily via renal excretion, with minimal systemic absorption, thus reducing the risk of systemic side effects.

Adverse effects

• Diarrhea
• Abdominal cramps
• Nausea
• Vomiting
• Electrolyte imbalances

Precautions

• Use with caution in patients with renal impairment
• May exacerbate gastrointestinal conditions

Pregnancy

Sorbitol is generally considered safe during pregnancy, but should be used under medical supervision.

Breast-feeding

Sorbitol is excreted in breast milk in small amounts; consult a healthcare provider before use.

Storage

Store in a cool, dry place, away from direct sunlight.

Formulations

• Oral solution
• Syrup

Indications

• Choline deficiency
• Cognitive enhancement
• Neuromuscular disorders
• Lipid metabolism disorders

Dosage

Children: Refer to specific guidelines or consult a healthcare provider for appropriate dosing.

Adults: Refer to specific guidelines or consult a healthcare provider for appropriate dosing.

Mechanism of action

Tricholine acts primarily as a source of choline, which is necessary for the synthesis of phosphatidylcholine, a major component of cell membranes. It also serves as a precursor for the neurotransmitter acetylcholine. By increasing the availability of choline, tricholine may enhance cholinergic signaling, which can influence various physiological functions, including cognitive processing and muscle contraction.

Pharmacodynamics

Tricholine influences several physiological pathways, mainly related to neurotransmission and lipid metabolism. By enhancing choline availability, it supports the synthesis of acetylcholine, which is involved in neuromuscular transmission and cognitive functions. Additionally, it may contribute to the maintenance of cell membrane integrity and function due to its role in phospholipid synthesis.

Pharmacokinetics

Following oral administration, tricholine is absorbed in the gastrointestinal tract, where it is subsequently metabolized to choline. The bioavailability of choline can be affected by dietary factors and the presence of other nutrients. Choline is distributed widely throughout the body, crossing the blood-brain barrier to participate in central nervous system functions. Its elimination occurs primarily via metabolic pathways, with excretion through urine.

Adverse effects

• Gastrointestinal disturbances
• Nausea
• Diarrhea
• Allergic reactions

Precautions

• Use with caution in patients with gastrointestinal disorders
• Monitor for allergic reactions in sensitive individuals

Pregnancy

The safety of tricholine during pregnancy has not been established. Use only if clearly needed.

Breast-feeding

Limited information is available on the excretion of tricholine in human milk. Exercise caution and consult a healthcare provider.

Storage

Store in a cool, dry place away from direct sunlight. Keep out of reach of children.

Formulations

• Capsules
• Tablets
• Powder for oral solution

Mechanism of action

Sorbitol exerts its laxative effect by drawing water into the large intestine, thereby stimulating bowel movements. ... Sorbitol exerts hygroscopic and/or local irritant action, drawing water from tissues into feces and reflexly stimulating evacuation. The polyol pathway consists of two enzymes aldose reductase (AR) and sorbitol dehydrogenase (SDH); the former is the first enzyme in the polyol pathway, that catalyzes the reduction of glucose to sorbitol, the latter is the second one, that converts sorbitol to fructose using by NAD(+) as a cofactor. ... SDH activity, the second step in the polyol pathway, might make a greater contribution to the etiology of diabetic retinopathy than does the first step involving AR. /This paper proposes/ a novel hypothesis that polymorphisms of SDH gene may be correlated with SDH gene expression levels in diabetic retinas, thus being a valuable genetic marker for diabetic retinopathy. It has been reported that sorbitol induces apoptosis in several cancer cell lines. ... In /this/ study, the intracellular signaling pathways of sorbitol-induced apoptosis in human K562 cells were investigated using both morphological analysis and DNA fragmentation technique. In this study, we demonstrated that sorbitol-induced apoptosis in human K562 cells is a concentration- and time-dependent manner. This sorbitol-induced apoptosis in human K562 cells was also accompanied by the up-regulation of Bax, and down-regulation of p-Bcl-2, but no effect on the levels of Bcl-X(L). Moreover, the sorbitol treatment resulted in a significant reduction of mitochondria membrane potential, increase in the release of mitochondrial cytochrome c (cyt c), and activation of caspase 3. Furthermore, treatment with caspase 3 inhibitor (z-DEVD-fmk) was capable of preventing the sorbitol-induced caspase 3 activity and cell death. These results clearly demonstrate that the induction of apoptosis by sorbitol involves multiple cellular/molecular pathways and strongly suggest that pro- and anti-apoptotic Bcl-2 family proteins, mitochondrial membrane potential, mitochondrial cyt c, and caspase 3, they all participate in sorbitol-induced apoptotic process in human K562 cells. Chronic diabetic complications, in particular, nephropathy, peripheral and autonomic neuropathy, "diabetic foot," retinopathy, and cardiovascular disease, remain the major cause of morbidity and mortality in patients with diabetes mellitus. Growing evidence indicates that both increased activity of the sorbitol pathway of glucose metabolism and enhanced oxidative stress are the leading factors in the pathogenesis of diabetic complications. The relation between the two mechanisms remains the area of controversy. One group has reported that increased sorbitol pathway activity has a protective rather than detrimental role in complication-prone tissues because the pathway detoxifies toxic lipid peroxidation products. Others put forward a so-called "unifying hypothesis" suggesting that activation of several major pathways implicated in diabetic complications (eg, sorbitol pathway) occurs due to increased production of superoxide anion radicals in mitochondria and resulting poly(ADP-ribose) polymerase activation. This review (a) presents findings supporting a key role for the sorbitol pathway in oxidative stress and oxidative stress-initiated downstream mechanisms of diabetic complications, and (b) summarizes experimental evidence against a detoxifying role of the sorbitol pathway, as well as the "unifying concept."